January 13, 2022
Daiichi Sankyo said on January 12 that it will close the offices of its US R&D subsidiary Plexxikon to maximize its investment in its three lead antibody-drug conjugate (ADC) assets including Enhertu (trastuzumab deruxtecan). Founded in 2001, San Francisco-based Plexxikon...read more